Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067104 · ClinicalTrials.gov registry record · Phase 2
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02067104: Clinical Trial Phase 2 study, sponsored by University of Arizona.
NCT02067104 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02067104, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
Primary Outcome
Measured by the incidence of biopsy confirmed BCC over a 24 month period
Interventions
- DRUG Placebo
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02-17 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 2 |
Why NCT02067104 stopped before completion
NCT02067104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02067104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02067104 about?
NCT02067104 is a clinical study titled "Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention". This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
What is the current status of trial NCT02067104?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-02-17. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02067104?
The interventions under investigation include: Placebo (DRUG), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT02067104?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02067104's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI